SCHEMBL22426188

SCHEMBL22426188

CC(C)c1cc(CC(C)c2ccnc(CC(C)c3cncnc3)n2)ncn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21516067 0.85 RXRA (0.31) —
SCHEMBL20341255 0.80 RXRA (0.30) —
SCHEMBL21653572 0.73 — —
SCHEMBL22645179 0.73 ALDH1A1 (0.32) —
SCHEMBL24185043 0.72 KDM4E (0.30) —
SCHEMBL19308850 0.70 RXRA (0.31) —
SCHEMBL20756637 0.69 ESR1 (0.36) —
SCHEMBL22725520 0.68 RXRA (0.30) —
SCHEMBL24517542 0.68 — —
SCHEMBL22374290 0.68 ESR1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345708-B2 Substituted imidazo[1,2-a]imidazoles as modulators of metabotropic glutamate receptor 4 activity HOFFMANN-LA ROCHE INC. (US) 2022-05-31 — — US disclosed
US-20200291033-A1 IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE HOFFMANN-LA ROCHE INC. (US) 2020-09-17 — — US disclosed
Send feedback